Q2 FY2026 · ended Jun 30, 2026 · Revenue $254.56M, +5.8% YoY · Filed Aug 6, 2026
Tandem Diabetes Care, Inc. (TNDM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $254.6 million and a net loss of $21.2 million. Free cash flow was -$38.7 million. As of Jun 30, 2026 it held $456.0 million in cash and investments and $739.3 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TNDM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1438133
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $254.6M | $247.2M | $290.4M | $249.3M | $240.7M |
| Operating income | -$13.8M | -$17.4M | $8.3M | -$22.9M | -$51.8M |
| Net income | -$21.2M | -$20.4M | -$589,000 | -$21.2M | -$52.4M |
| Diluted EPS | -$0.31 | -$0.30 | -$0.01 | -$0.31 | -$0.78 |
| Operating cash flow | -$34.6M | $11.1M | $9.8M | $8.3M | -$9.5M |
| Free cash flow | -$38.7M | $4.8M | $3.1M | $4.2M | -$15.7M |
| Total assets | $1.2B | $1.2B | $881.1M | $874.7M | $875.7M |
| Total liabilities | $1.0B | $1.0B | $725.9M | $741.7M | $742.5M |
| Stockholders' equity | $130.4M | $132.4M | $155.2M | $133.0M | $133.3M |
| Cash and investments | $456.0M | $570.3M | $292.7M | $319.1M | $315.4M |
| Total debt | $739.3M | $734.7M | $444.5M | $449.3M | $449.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 8-K |
Current report
Officer or director change
|
May 15, 2026 | May 11, 2026 |
All 1006 Tandem Diabetes Care, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.